The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Cadence Pharmaceuticals met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP loss per share contracted.
Margins increased across the board.
Cadence Pharmaceuticals tallied revenue of $13.9 million. The 11 analysts polled by S&P Capital IQ anticipated revenue of $14.1 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $3.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.19. The five earnings estimates compiled by S&P Capital IQ anticipated -$0.19 per share. GAAP EPS were -$0.19 for Q3 versus -$0.34 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 56.3%, 2,180 basis points better than the prior-year quarter. Operating margin was -106.5%, 47,840 basis points better than the prior-year quarter. Net margin was -114.3%, 50,220 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $17.9 million. On the bottom line, the average EPS estimate is -$0.16.
Next year's average estimate for revenue is $51.1 million. The average EPS estimate is -$0.86.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 64 members out of 101 rating the stock outperform, and 37 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give Cadence Pharmaceuticals a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cadence Pharmaceuticals is outperform, with an average price target of $5.65.
- Add Cadence Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.